Gilead's Lenacapavir Injection Shows 96% Effectiveness in HIV Prevention, But Cost Poses Challenge

Nov 30, 2024, 04:25 AM

Recent clinical trials have shown that lenacapavir, an active ingredient developed by Gilead, significantly reduces the risk of HIV infection. Administered through a twice-yearly injection, the drug has demonstrated a 96% effectiveness rate in preventing HIV, potentially outperforming traditional oral pre-exposure prophylaxis (PrEP). This breakthrough has been described as a 'great relief' and could revolutionize HIV prevention strategies. However, the high cost of lenacapavir might pose a challenge to its widespread adoption in the fight against the disease.